Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model

Infliximab (IFX), a TNF-α blocking chimeric monoclonal antibody, induces clinical response and mucosal healing in patients with inflammatory bowel disease (IBD). However, systemic administration of this agent ...

from Most Recent Articles: Journal of Nanobiotechnology https://ift.tt/3izajIo
via IFTTT